U.S. markets open in 7 hours 52 minutes
  • S&P Futures

    -15.75 (-0.38%)
  • Dow Futures

    -136.00 (-0.40%)
  • Nasdaq Futures

    -83.00 (-0.62%)
  • Russell 2000 Futures

    -13.30 (-0.60%)
  • Crude Oil

    +0.07 (+0.11%)
  • Gold

    -5.50 (-0.30%)
  • Silver

    -0.16 (-0.59%)

    -0.0021 (-0.17%)
  • 10-Yr Bond

    0.0000 (0.00%)
  • Vix

    +2.18 (+11.09%)

    -0.0020 (-0.14%)

    +0.2210 (+0.20%)

    +2,565.32 (+4.67%)
  • CMC Crypto 200

    +1,314.31 (+541.58%)
  • FTSE 100

    -175.69 (-2.47%)
  • Nikkei 225

    -400.07 (-1.40%)

Blog Coverage Celldex Acquires Cancer Medicine Company for $62.5 Million

Upcoming AWS Coverage on Immunomedics Post-Earnings Results

LONDON, UK / ACCESSWIRE / November 3, 2016 / Active Wall St. blog coverage looks at the headline from Celldex Therapeutics, Inc. (NASDAQ: CLDX) as the company announced on November 01st, 2016, that it has entered into a definitive agreement to acquire Kolltan Pharmaceuticals, Inc., a privately held clinical-stage company focused on the discovery and development of novel, antibody-based drugs targeting receptor tyrosine kinases (RTKs), for $62.5 million in stock. Register with us now for your free membership and blog access at: http://www.activewallst.com/register/.

Celldex Therapeutics is expected to report third quarter 2016 results on November 3, 2016. One of its competitors within the Biotechnology space, Immunomedics Inc. (NASDAQ: IMMU), reported its financial results for Q1 ended September 30, 2016, after the close of U.S. financial markets on Wednesday, November 2, 2016. AWS will be initiating a research report on Immunomedics in the coming days.

Today, AWS is promoting its blog coverage on CLDX; touching on stocks like IMMU. Get all of our free blog coverage and more by clicking on the link below:



Kolltan has reported clinical and preclinical data that its drug candidates can help overcome tumor resistance mechanisms associated with current tyrosine kinase inhibitors and seen in patients who have failed other cancer therapies. Celldex believes Kolltan's clinical candidates and preclinical platform are highly compatible with the Company's scientific approach and can be developed independently and in combination with Celldex's existing product candidates.

Anthony Marucci, Co-founder, President and Chief Executive Officer of Celldex Therapeutics stated:

"The acquisition of Kolltan provides Celldex with a truly unique platform of antibodies targeting receptor tyrosine kinases which we believe are highly compatible with our pipeline. We believe this acquisition complements our leadership position in immuno-oncology and enhances our ability to develop targeted therapeutic regimens to dramatically improve patient outcomes."

What Will Celldex Gain from the Acquisition?

Upon closing of the acquisition of Kolltan, Celldex Therapeutics' clinical pipeline will include seven drug candidates including therapeutic antibodies, antibody-drug conjugates (ADCs) and immune system modulators, which are being tested in a range of difficult-to-treat indications in oncology. This broad pipeline allows for novel combination approaches, several of which are already under study. In addition, Celldex Therapeutics would have two active preclinical programs.

Some of the Key drugs in the pipeline in Kolltan's portfolio are:

KTN0158 – a humanized monoclonal antibody that is a potent inhibitor of KIT activation in tumor cells and mast cells; currently in a Phase 1 dose escalation study in refractory gastrointestinal stromal tumors (GIST). KTN0158 prevents KIT activation by blocking receptor dimerization. This mechanism may be effective even in tumors harboring the most common resistant mutations to Gleevec® and is unlikely to drive resistance. Preclinical data demonstrate that KIT inhibition in certain immune cells with KTN0158 enhances the activity of checkpoint blockade.

KTN3379 – a human monoclonal antibody designed to block the activity of ErbB3 (HER3); clinical activity including meaningful responses and stable disease has been observed in a Phase 1b study in cetuximab (Erbitux®) refractory patients in head and neck squamous cell carcinoma and in BRAF-mutant non-small cell lung cancer (NSCLC). The proposed mechanism of action for KTN3379 sets it apart from other drugs in development in this class due to its ability to block both ligand-independent and ligand-dependent ErbB3 signaling by binding to a unique epitope. It also has a favorable pharmacologic profile, including a longer half-life relative to other drug candidates in this class.

A multi-faceted TAM program – a broad antibody discovery effort underway to generate antibodies that modulate the TAM family of RTKs, comprised of Tyro3, AXL and MerTK, which are expressed on tumor-infiltrating macrophages, dendritic cells and some tumors. In oncology, as with PD-1 and other checkpoints, TAMs regulate the immune response to cancer.

Transaction Terms

Under terms of the agreement, Celldex Therapeutics will acquire Kolltan in a stock-for-stock transaction, in which the upfront payment represents an equity value of approximately $62.5 million. In addition, Kolltan's shareholders are eligible to receive additional payments of up to $172.5 million upon the completion of specific development, regulatory, and commercial milestones. The transaction, which is subject to approval from Kolltan's stockholder and other customary closing conditions, is expected to be completed by end of 2016. The Boards of Directors of both Celldex Therapeutics and Kolltan Pharmaceuticals have already approved the transaction.

Stock Performance

On Wednesday, Celldex Therapeutics' stock closed the trading session at $3.15, marginally up by 0.96% from its previous closing price of $3.12. A total volume of 2.45 million shares have exchanged hands, which was higher than the 3-month average volume of 2.18 million shares. The stock currently has a market cap of $319.69 million.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.


For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com
Phone number: 1-858-257-3144

Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street